Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Intrinsic Value
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. [ Read More ]
The intrinsic value of one YMAB stock under the Base Case scenario is 21.68 USD. Compared to the current market price of 16.5 USD, Y-mAbs Therapeutics Inc is Undervalued by 24%.
Valuation Backtest
Y-mAbs Therapeutics Inc
Run backtest to discover the historical profit from buying and selling YMAB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Y-mAbs Therapeutics Inc's business.
What risks and challenges
does Y-mAbs Therapeutics Inc face in the near future?
Summarize the latest earnings report
of Y-mAbs Therapeutics Inc.
Provide P/E
for Y-mAbs Therapeutics Inc and its competitors.
Balance Sheet Decomposition
Y-mAbs Therapeutics Inc
Current Assets | 111.1m |
Cash & Short-Term Investments | 78.6m |
Receivables | 22.5m |
Other Current Assets | 10m |
Non-Current Assets | 16.8m |
PP&E | 1.6m |
Intangibles | 2.6m |
Other Non-Current Assets | 12.5m |
Current Liabilities | 20.1m |
Accounts Payable | 6.1m |
Accrued Liabilities | 14.1m |
Non-Current Liabilities | 6.8m |
Other Non-Current Liabilities | 6.8m |
Earnings Waterfall
Y-mAbs Therapeutics Inc
Revenue
|
84.8m
USD
|
Cost of Revenue
|
-11.4m
USD
|
Gross Profit
|
73.5m
USD
|
Operating Expenses
|
-94.6m
USD
|
Operating Income
|
-21.2m
USD
|
Other Expenses
|
-237k
USD
|
Net Income
|
-21.4m
USD
|
Free Cash Flow Analysis
Y-mAbs Therapeutics Inc
What is Free Cash Flow?
YMAB Profitability Score
Profitability Due Diligence
Y-mAbs Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Y-mAbs Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
YMAB Solvency Score
Solvency Due Diligence
Y-mAbs Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Y-mAbs Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YMAB Price Targets Summary
Y-mAbs Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for YMAB is 20.4 USD with a low forecast of 10.1 USD and a high forecast of 27.3 USD.
Ownership
YMAB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
YMAB Price
Y-mAbs Therapeutics Inc
Average Annual Return | -9.93% |
Standard Deviation of Annual Returns | 68.61% |
Max Drawdown | -95% |
Market Capitalization | 720.6m USD |
Shares Outstanding | 43 777 100 |
Percentage of Shares Shorted | 5.96% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 148 full-time employees. The company went IPO on 2018-09-21. The company is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. The company also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The firm is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.
Contact
IPO
Employees
Officers
The intrinsic value of one YMAB stock under the Base Case scenario is 21.68 USD.
Compared to the current market price of 16.5 USD, Y-mAbs Therapeutics Inc is Undervalued by 24%.